<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24223" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Leuprolide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Swayzer</surname>
            <given-names>Dallas V.</given-names>
          </name>
          <aff>California Northstate University COM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gerriets</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>California Northstate University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dallas Swayzer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Valerie Gerriets declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24223.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Leuprolide is a medication used in the management and treatment of prostate cancer, endometriosis, uterine fibroids, precocious puberty, and other sex hormone-related conditions. It is in the GnRH agonist class of medications. This activity reviews the indications, mechanism of action, contraindications, monitoring protocols, and other vital factors pertinent for members of an interprofessional team managing the care of patients with prostate cancer and other sex hormone-related disorders.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of leuprolide.</p></list-item><list-item><p>Identify the most common adverse reactions associated with leuprolide therapy.</p></list-item><list-item><p>Summarize management considerations for patients on leuprolide therapy.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team to ensure the appropriate selection of candidates for leuprolide therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24223&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24223">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24223.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Leuprolide is an FDA-approved gonadotropin-releasing hormone (GnRH) agonist used for the management of endometriosis, uterine leiomyomata (also known as uterine fibroids), treatment of central precocious puberty in children, and advanced prostate cancer. Off-label uses include management of breast cancer, hormone therapy for male to female transgender patients, premenopausal ovarian suppression, and management of paraphilia and hypersexuality.<xref ref-type="bibr" rid="article-24223.r1">[1]</xref><xref ref-type="bibr" rid="article-24223.r2">[2]</xref><xref ref-type="bibr" rid="article-24223.r3">[3]</xref></p>
        <p>In patients with endometriosis receiving this medication, the goal is to reduce endometriotic lesions and improve pelvic pain/tenderness, dysmenorrhoea, and dyspareunia.<xref ref-type="bibr" rid="article-24223.r2">[2]</xref> It can be used as an initial form of management but is only usable for a maximum duration of 6 months. It is administered either as a monotherapy or in combination with norethindrone acetate to reduce bone mineral density loss. If symptoms recur, the combination method is an option as a single retreatment course for an additional six months.<xref ref-type="bibr" rid="article-24223.r2">[2]</xref>&#x000a0;</p>
        <p>In advanced prostate cancer, leuprolide is used as a palliative treatment to help reduce comorbidities and improve quality of life. Leuprolide lowers testosterone levels, which in turn minimizes the stimulatory effect it normally has on androgen-sensitive prostate cancer cells, therefore causing them to undergo apoptosis.<xref ref-type="bibr" rid="article-24223.r4">[4]</xref> &#x000a0;</p>
        <p>For uterine leiomyomata, leuprolide is effective in multiple ways. Preoperatively it can be used along with iron to treat anemia, reduce fibroid volume, and ultimately reduce bleeding during surgery. Even if the patient isn&#x02019;t undergoing surgery, leuprolide can be used to reduce fibroid size and improve symptoms related to the fibroids.<xref ref-type="bibr" rid="article-24223.r5">[5]</xref></p>
        <p>In treating children with central precocious puberty with leuprolide, the goal is to slow down the progression of the secondary sex characteristics until an age when they are appropriate. If left untreated, these patients typically have diminished adult height. With the use of leuprolide, the predicted adult height increases because it slows down the closing of the growth plates. Leuprolide discontinuation should merit consideration when at the appropriate time for puberty.<xref ref-type="bibr" rid="article-24223.r6">[6]</xref> &#x000a0;</p>
      </sec>
      <sec id="article-24223.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Leuprolide acetate is a GnRH receptor agonist, also called a GnRH analog. Initially, the administration of leuprolide causes stimulation of pituitary gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which leads to an increase in steroidogenesis in ovaries and testes; thus resulting in increased&#x000a0;estrogen in females and increased testosterone and dihydrotestosterone in males.<xref ref-type="bibr" rid="article-24223.r7">[7]</xref> With continuous administration, the levels of gonadotropins and gonadal steroids fall. Ultimately, continuous use of leuprolide decreases levels of testosterone in males and estrogen in females by inhibiting LH and FSH production.<xref ref-type="bibr" rid="article-24223.r2">[2]</xref></p>
      </sec>
      <sec id="article-24223.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Leuprolide acetate is administrable through an intramuscular or subcutaneous injection.<xref ref-type="bibr" rid="article-24223.r2">[2]</xref> The patient can receive injections in 1, 3, 4, or 6-month increments, and the length of time determines the specific dosage in between each injection.<xref ref-type="bibr" rid="article-24223.r3">[3]</xref><xref ref-type="bibr" rid="article-24223.r8">[8]</xref><xref ref-type="bibr" rid="article-24223.r9">[9]</xref>&#x000a0;For instance, having an injection once every six months will require a higher dose of medication compared to the injection once a month. Dosages should not be combined because there are different release characteristics.</p>
      </sec>
      <sec id="article-24223.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse reactions are reported to be different in children versus adults. Typically leuprolide is well tolerated in children, but the most common complaint is local pain at the injection site, which occurs in 10% of cases. Other common reactions include weight change, mood changes, skin rash, acne vulgaris, seborrhea, vaginal discharge, vaginal hemorrhage, and vaginitis. Reports also exist of anaphylactic reactions.<xref ref-type="bibr" rid="article-24223.r10">[10]</xref> In adults, the most common adverse reactions are injection site pain, flushing, hot flashes, headaches, and migraines. Other reported adverse effects include alopecia, nausea, vomiting, diarrhea, GI upset, fatigue, edema, insomnia, upper respiratory infection, fever, nasal congestion, altered mood, weight gain, vaginitis, testicular atrophy, weakness, dizziness, hyperlipidemia, hyperglycemia, impotence, decreased libido, dermatological changes, and arthropathy. Reduced fertility has been noted but typically reverses with the cessation of the drug. There are also reports of amenorrhea in women.<xref ref-type="bibr" rid="article-24223.r2">[2]</xref><xref ref-type="bibr" rid="article-24223.r9">[9]</xref><xref ref-type="bibr" rid="article-24223.r11">[11]</xref><xref ref-type="bibr" rid="article-24223.r12">[12]</xref></p>
      </sec>
      <sec id="article-24223.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to leuprolide therapy include hypersensitivity to leuprolide or any other gonadotropin-releasing hormone agonists.<xref ref-type="bibr" rid="article-24223.r13">[13]</xref> This medication should not be used in women who are or may become pregnant. A negative pregnancy test is necessary before starting the medication. Although this drug typically inhibits ovulation and stops menstruation, pregnancy can occur and therefore patients should be placed on a nonhormonal contraceptive while on leuprolide therapy. Also, it should not be used in women who are breastfeeding, and it is contraindicated in those who have undiagnosed vaginal bleeding. Caution should be taken in giving leuprolide to patients with risk factors for bone loss and decreased bone density, as well as patients with heart failure or preexisting heart disease.<xref ref-type="bibr" rid="article-24223.r14">[14]</xref> Finally, leuprolide is not a therapeutic choice in postmenopausal women.&#x000a0;</p>
      </sec>
      <sec id="article-24223.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring parameters vary depending on the condition receiving therapy with leuprolide. For all uses, bone mineral density&#x000a0;and psychiatric symptoms require monitoring. Risk factors for bone loss include osteoporosis or a strong family history of it, chronic medication use that can decrease bone density such as anticonvulsants or corticosteroids, and chronic tobacco and alcohol use. Caution is necessary when treating these patients with leuprolide. Mood changes such as emotional lability, aggression, irritability, anger, and impatience are all possible in patients on leuprolide therapy; thus, the development or worsening of these symptoms is essential to monitor. Use leuprolide with caution in patients diagnosed with depression.<xref ref-type="bibr" rid="article-24223.r15">[15]</xref>&#x000a0;</p>
        <p>When using this drug to manage women with endometriosis, pregnancy must initially be ruled out with a negative pregnancy test. Endometrial pain can become exacerbated at first with therapy, but the clinician should monitor the pain throughout the use of leuprolide.&#x000a0;</p>
        <p>For the treatment of precocious puberty in children, LH and FSH blood serum levels must be monitored, and height and bone age should be measured every 6&#x000a0;to 12 months. Testosterone levels in males and estradiol levels in females should get checked as well, and tanner staging is essential to monitor before, during, and after treatment.<xref ref-type="bibr" rid="article-24223.r6">[6]</xref>&#x000a0;</p>
        <p>Pediatric females using leuprolide may experience menses or spotting during the first two months of treatment, but medical staff should follow patients to check for continued bleeding after two months.<xref ref-type="bibr" rid="article-24223.r6">[6]</xref>&#x000a0;</p>
        <p>For the treatment of prostate cancer, providers should monitor FSH and LH levels, serum testosterone levels, and prostate-specific antigen levels. Fatigue, weakness, and urinary tract obstruction all merit vigilance during the initial treatment. Screening for diabetes should take place before starting therapy, as leuprolide can worsen glycemic control. Blood glucose and HbA1c should get periodically measured throughout therapeutic use. Electrocardiograms and electrolyte levels should be monitored occasionally, as well.<xref ref-type="bibr" rid="article-24223.r16">[16]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-24223.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Leuprolide might cause fetal harm when given to a pregnant woman. In clinical trials, there has not been any reported overdose with leuprolide. Studies of increased doses of leuprolide show that patients tolerate the drug well.<xref ref-type="bibr" rid="article-24223.r12">[12]</xref><xref ref-type="bibr" rid="article-24223.r17">[17]</xref> However, practitioners should avoid using dosage forms of leuprolide that contain benzyl alcohol in neonates. "Gasping syndrome" is fatal toxicity that can occur in neonates, and it has correlated with large amounts of benzyl alcohol. This gasping syndrome includes CNS dysfunction, respiratory distress, metabolic acidosis, and hypotension.<xref ref-type="bibr" rid="article-24223.r18">[18]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-24223.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Sex-hormone related disorders present with more than just the physiological findings to treat. For instance, precocious puberty not only shows as physical changes but also has mental effects on a child and how they are perceived in the world. Therefore, an interprofessional team of healthcare providers is necessary to treat these patients. These interprofessional teams should include physicians, nurses, pharmacists, psychologists, and others. The same applies to an interprofessional team that will treat patients with advanced prostate cancer. When the clinician or specialist initiates leuprolide therapy, a pharmacist should perform drug interaction checking and verify the dosage. Nursing can counsel the patient regarding dosing and administration, as well as potential adverse events that will require them to contact the prescriber's office. Pharmacists and nurses need to notify the clinicians if they have any concerns about the patient's therapy, as this type of interprofessional interaction will improve patient outcomes. [Level 5]</p>
        <p>There will be many different specialties that need to communicate effectively and bring about better results for the patient. With the many different uses of leuprolide, physicians, nurses, and pharmacists must have a good understanding of the clinical applications and side effects of the drug. Also, a team of interprofessional researchers found that leuprolide is helpful in IVF treatments. The study gave one group leuprolide and gonadotropins and compared it to a control group that only received gonadotropins. It found that pregnancy rates increased in the experimental group.<xref ref-type="bibr" rid="article-24223.r19">[19]</xref>&#x000a0;[Level 3] With increased interprofessional knowledge and communication about leuprolide, research may uncover more therapeutic uses for the drug.</p>
      </sec>
      <sec id="article-24223.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24223&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24223">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24223/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24223">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24223.s11">
        <title>References</title>
        <ref id="article-24223.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Meethal</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Bowen</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Atwood</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Leuprolide acetate: a drug of diverse clinical applications.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>1851</fpage>
            <page-range>1851-63</page-range>
            <pub-id pub-id-type="pmid">17970643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plosker</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.</article-title>
            <source>Drugs</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>930</fpage>
            <page-range>930-67</page-range>
            <pub-id pub-id-type="pmid">7533699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boccardo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rubagotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amoroso</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Agostara</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Amadori</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gallo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Iacobelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Massidda</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mesiti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pacini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tomao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paganuzzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marroni</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>1999</year>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>461</fpage>
            <page-range>461-6</page-range>
            <pub-id pub-id-type="pmid">10321505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosario</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Davey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK.</article-title>
            <source>World J Urol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>12</issue>
            <fpage>1601</fpage>
            <page-range>1601-1609</page-range>
            <pub-id pub-id-type="pmid">27097892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bastianelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rosato</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brosens</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Benagiano</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Uterine fibroids: an update on current and emerging medical treatment options.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2019</year>
            <volume>15</volume>
            <fpage>157</fpage>
            <page-range>157-178</page-range>
            <pub-id pub-id-type="pmid">30774352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eugster</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Central Precocious Puberty: Update on Diagnosis and Treatment.</article-title>
            <source>Paediatr Drugs</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>273</fpage>
            <page-range>273-81</page-range>
            <pub-id pub-id-type="pmid">25911294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cook</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sheridan</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Development of GnRH antagonists for prostate cancer: new approaches to treatment.</article-title>
            <source>Oncologist</source>
            <year>2000</year>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>162</fpage>
            <page-range>162-8</page-range>
            <pub-id pub-id-type="pmid">10794807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsai</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Twu</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Yen</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YJ</given-names>
              </name>
            </person-group>
            <article-title>Low-dose add-back therapy during postoperative GnRH agonist treatment.</article-title>
            <source>Taiwan J Obstet Gynecol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-9</page-range>
            <pub-id pub-id-type="pmid">26927249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmid</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Untch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koss&#x000e9;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bondar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vassiljev</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tarutinov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lehmann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Maubach</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meurer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wallwiener</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Possinger</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.</article-title>
            <source>J Clin Oncol</source>
            <year>2007</year>
            <month>Jun</month>
            <day>20</day>
            <volume>25</volume>
            <issue>18</issue>
            <fpage>2509</fpage>
            <page-range>2509-15</page-range>
            <pub-id pub-id-type="pmid">17577027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carel</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Eugster</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Rogol</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghizzoni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Palmert</surname>
                <given-names>MR</given-names>
              </name>
              <collab>ESPE-LWPES GnRH Analogs Consensus Conference Group</collab>
              <name>
                <surname>Antoniazzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Berenbaum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bourguignon</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Coste</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Deal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jahnukainen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Juul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaplowitz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lahlou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Merke</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Neely</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Oostdijk</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Phillip</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenfield</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Shulman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Styne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tauber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wit</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Consensus statement on the use of gonadotropin-releasing hormone analogs in children.</article-title>
            <source>Pediatrics</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>123</volume>
            <issue>4</issue>
            <fpage>e752</fpage>
            <page-range>e752-62</page-range>
            <pub-id pub-id-type="pmid">19332438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spry</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Galv&#x000e3;o</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>La Bianca</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.</article-title>
            <source>BJU Int</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>104</volume>
            <issue>6</issue>
            <fpage>806</fpage>
            <page-range>806-12</page-range>
            <pub-id pub-id-type="pmid">19281463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mauras</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Neely</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mattia-Goldberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chwalisz</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>May</month>
            <volume>97</volume>
            <issue>5</issue>
            <fpage>1572</fpage>
            <page-range>1572-80</page-range>
            <pub-id pub-id-type="pmid">22344198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000fc;chinger</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Mijatovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rustemeyer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hompes</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Anaphylactic reaction to different gonadotropin-releasing hormone agonists for the treatment of endometriosis.</article-title>
            <source>Am J Med Sci</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>341</volume>
            <issue>3</issue>
            <fpage>240</fpage>
            <page-range>240-2</page-range>
            <pub-id pub-id-type="pmid">21233692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bienz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review.</article-title>
            <source>Bonekey Rep</source>
            <year>2015</year>
            <volume>4</volume>
            <fpage>716</fpage>
            <pub-id pub-id-type="pmid">26131363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sadler Gallagher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Stokes</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Laufer</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Hornstein</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>DiVasta</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.</article-title>
            <source>J Pediatr Adolesc Gynecol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>215</fpage>
            <page-range>215-222</page-range>
            <pub-id pub-id-type="pmid">26927501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Chetner</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Bruner</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Leibenhaut</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Husain</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Rotman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Souhami</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Shipley</surname>
                <given-names>WU</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy and short-term androgen deprivation for localized prostate cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Jul</month>
            <day>14</day>
            <volume>365</volume>
            <issue>2</issue>
            <fpage>107</fpage>
            <page-range>107-18</page-range>
            <pub-id pub-id-type="pmid">21751904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spitz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mattia-Goldberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Donnelly</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chwalisz</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer.</article-title>
            <source>Prostate Cancer Prostatic Dis</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-9</page-range>
            <pub-id pub-id-type="pmid">22025196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <article-title>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs.</article-title>
            <source>Pediatrics</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>268</fpage>
            <page-range>268-78</page-range>
            <pub-id pub-id-type="pmid">9024461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24223.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chetkowski</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kruse</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Nass</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Improved pregnancy outcome with the addition of leuprolide acetate to gonadotropins for in vitro fertilization.</article-title>
            <source>Fertil Steril</source>
            <year>1989</year>
            <month>Aug</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>250</fpage>
            <page-range>250-5</page-range>
            <pub-id pub-id-type="pmid">2502439</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
